The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The full Galactic-HF data were supposed to have suggested a path forward. Instead they point the way to disagreement.
A theoretical pivotal trial success fails to back omecamtiv’s commercial promise and leaves Amgen’s pipeline in dire straits.
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.